title: Cyclooxygenase-2 inhibitors dilemma in cardiovascular medicine: are all family members bad players?
abstract: Cyclooxygenase-2 (COX-2) inhibitors dilemma in cardiovascular medicine has not been resolved yet. The cardiovascular safety of selective COX-2 inhibitors other than rofecoxib is uncertain. Given the ongoing controversy surrounding the use of COX-2 inhibitors, further clinical studies with different types of drugs are required to establish safety and therapeutic benefit in patients with coronary artery disease.
authors.forename: Turgay
authors.initials: T
authors.lastname: Celik
authors.forename: Atila
authors.initials: A
authors.lastname: Iyisoy
authors.forename: Hurkan
authors.initials: H
authors.lastname: Kursaklioglu
authors.forename: U Cagdas
authors.initials: UC
authors.lastname: Yuksel
mesh_terms: D002319:Cardiovascular System / Q000187:drug effects*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans
chemical_list: D052246:Cyclooxygenase 2 Inhibitors